Sectoral Asset Management Inc. Increases Stake in Amgen Inc. $AMGN

Sectoral Asset Management Inc. increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 26.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 13,070 shares of the medical research company’s stock after purchasing an additional 2,730 shares during the quarter. Amgen accounts for approximately 3.4% of Sectoral Asset Management Inc.’s portfolio, making the stock its 6th largest position. Sectoral Asset Management Inc.’s holdings in Amgen were worth $4,278,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of AMGN. Capital World Investors grew its position in Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after acquiring an additional 1,935,876 shares during the last quarter. Vanguard Group Inc. grew its position in Amgen by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares during the last quarter. National Bank of Canada FI grew its position in Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after acquiring an additional 863,216 shares during the last quarter. Van ECK Associates Corp grew its position in Amgen by 71.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after acquiring an additional 567,400 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in Amgen by 91.6% during the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock worth $221,607,000 after acquiring an additional 375,463 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. UBS Group raised their price target on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Morgan Stanley set a $332.00 price target on Amgen in a research report on Friday, May 1st. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $355.19.

Amgen Price Performance

Shares of AMGN stock opened at $339.30 on Monday. The firm has a market cap of $183.11 billion, a P/E ratio of 23.61, a P/E/G ratio of 3.41 and a beta of 0.44. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The business’s 50 day moving average price is $345.10 and its 200-day moving average price is $344.72. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.37 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.15%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen expanded its lung cancer pipeline by launching a phase 1b study testing a tarlatamab combination in small cell lung cancer, which could improve the company’s oncology growth prospects if the data are encouraging. Amgen Expands Lung Cancer Pipeline With New Tarlatamab Combo Study
• Positive Sentiment: Several reports highlighted Amgen as a long-term value/dividend and pipeline story, citing upside potential and analyst support such as an Overweight rating from Piper Sandler, reinforcing confidence in the company’s revenue growth outlook. Why Wall Street Thinks This Dividend Stock Could Jump 30%
• Positive Sentiment: Amgen shareholders reaffirmed the board, executive pay and auditors, which signals governance stability and removes a potential overhang. Amgen Shareholders Reaffirm Board, Pay and Auditors
• Neutral Sentiment: Amgen appointed Thomas Dittrich as chief financial officer, a management update that should be watched for any strategic or capital-allocation changes, but is not clearly a near-term stock catalyst. CFOs On the Move: Week ending May 22
• Negative Sentiment: Investor focus remains on safety concerns around Tavneos after reported patient deaths in Japan prompted restrictions on new prescriptions and raised the risk of withdrawal requests in the U.S., creating a potential earnings and sentiment headwind for Amgen. A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
• Negative Sentiment: News that doctors in Japan could again prescribe Tavneos to new patients only partially eases concerns, because the drug still carries liver-injury warnings and the broader safety controversy may continue to pressure sentiment. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.